An Open-label, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JMKX003948 Tablets in Patients With Renal Cell Carcinoma
Latest Information Update: 18 Jul 2024
At a glance
- Drugs JMKX 003948 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jemincare
Most Recent Events
- 09 Jul 2024 Status changed from not yet recruiting to recruiting.
- 14 Mar 2024 Status changed from planning to not yet recruiting.
- 28 Dec 2023 New trial record